Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of “Moderate Buy” from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $4.1875.

LUCD has been the topic of several recent analyst reports. Maxim Group cut their price objective on Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, May 15th. BTIG Research reissued a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research note on Thursday, March 26th. Finally, Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday.

Insider Buying and Selling

In related news, Director Dennis Matheis acquired 245,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $1.00 per share, with a total value of $245,000.00. Following the transaction, the director owned 1,033,443 shares of the company’s stock, valued at $1,033,443. The trade was a 31.07% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Lucid Diagnostics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Two Seas Capital LP bought a new position in shares of Lucid Diagnostics during the third quarter worth about $3,030,000. Ghisallo Capital Management LLC acquired a new stake in Lucid Diagnostics in the 3rd quarter valued at approximately $2,990,000. Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 420.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after acquiring an additional 1,274,194 shares in the last quarter. Masters Capital Management LLC lifted its stake in Lucid Diagnostics by 46.6% in the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock valued at $4,039,000 after acquiring an additional 1,272,000 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in Lucid Diagnostics by 38.3% during the 4th quarter. Aberdeen Group plc now owns 3,457,894 shares of the company’s stock worth $3,769,000 after acquiring an additional 957,894 shares during the last quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Stock Performance

Shares of NASDAQ LUCD opened at $1.06 on Thursday. Lucid Diagnostics has a 52-week low of $0.90 and a 52-week high of $1.63. The stock has a market cap of $216.27 million, a P/E ratio of -2.27 and a beta of 1.07. The firm has a 50 day moving average price of $1.03 and a 200 day moving average price of $1.17.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.38 million. Analysts predict that Lucid Diagnostics will post -0.23 earnings per share for the current fiscal year.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.